-
Je něco špatně v tomto záznamu ?
The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells
Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M, Hrusak O, Trka J
Jazyk angličtina Země Spojené státy americké
Grantová podpora
NR8316
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Free Medical Journals
od 1995 do Před 1 rokem
Freely Accessible Science Journals
od 1995
Open Access Digital Library
od 1995-01-01
Open Access Digital Library
od 1995-01-01
- MeSH
- apoptóza účinky záření MeSH
- granzymy genetika MeSH
- histondeacetylasy MeSH
- inhibitory histondeacetylas MeSH
- lidé MeSH
- lymfoidní leukemie genetika patologie MeSH
- lymfopoéza genetika účinky léků MeSH
- nádorové buňky kultivované MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- proliferace buněk účinky léků MeSH
- protein PEBP2A2 fyziologie genetika MeSH
- protoonkogenní proteiny c-ets fyziologie genetika MeSH
- regulace genové exprese u leukemie účinky léků MeSH
- represorové proteiny fyziologie genetika MeSH
- stanovení celkové genové exprese MeSH
- Check Tag
- lidé MeSH
PURPOSE: Chimeric transcription factor ETV6/RUNX1 (TEL/AML1) is believed to cause pathologic block in lymphoid cell development via interaction with corepressor complex and histone deacetylase. We wanted to show the regulatory effect of ETV6/RUNX1 and its reversibility by histone deacetylase inhibitors (HDACi), as well as to identify potential ETV6/RUNX1-regulated genes. EXPERIMENTAL DESIGN: We used luciferase assay to show the interaction of ETV6/RUNX1 protein, ETV6/RUNX1-regulated gene, and HDACi. To identify ETV6/RUNX1-regulated genes, we used expression profiling and HDACi in lymphoid cells. Next, using the flow cytometry and quantitative reverse transcription-PCR, we measured differentiation changes in gene and protein expression after HDACi treatment. RESULTS: Luciferase assay showed repression of granzyme B expression by ETV6/RUNX1 protein and the reversibility of this effect by HDACi. Proving this regulatory role of ETV6/RUNX1, we identified, using complex statistical analysis, 25 genes that are potentially regulated by ETV6/RUNX1 protein. In four selected genes with known role in the cell cycle regulation (JunD, ACK1, PDGFRB, and TCF4), we confirmed expression changes after HDACi by quantitative analysis. After HDACi treatment, ETV6/RUNX1-positive cells showed immunophenotype changes resembling differentiation process compared with other leukemic cells (BCR/ABL, ETV6/PDGFRB positive). Moreover, ETV6/RUNX1-positive leukemic cells accumulated in G(1)-G(0) phase after HDACi whereas other B-lineage leukemic cell lines showed rather unspecific changes including induction of apoptosis and decreased proliferation. CONCLUSIONS: Presented data support the hypothesis that HDACi affect ETV6/RUNX1-positive cells via direct interaction with ETV6/RUNX1 protein and that treatment with HDACi may release aberrant transcription activity caused by ETV6/RUNX1 chimeric transcription factor.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07526550
- 003
- CZ-PrNML
- 005
- 20131015144834.0
- 008
- 090727s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Starková, Júlia, $d 1977- $7 xx0106984
- 245 14
- $a The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells / $c Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M, Hrusak O, Trka J
- 314 __
- $a Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology/Oncology, 2nd Medical School, Charles University Prague, Prague, Czech Republic
- 520 9_
- $a PURPOSE: Chimeric transcription factor ETV6/RUNX1 (TEL/AML1) is believed to cause pathologic block in lymphoid cell development via interaction with corepressor complex and histone deacetylase. We wanted to show the regulatory effect of ETV6/RUNX1 and its reversibility by histone deacetylase inhibitors (HDACi), as well as to identify potential ETV6/RUNX1-regulated genes. EXPERIMENTAL DESIGN: We used luciferase assay to show the interaction of ETV6/RUNX1 protein, ETV6/RUNX1-regulated gene, and HDACi. To identify ETV6/RUNX1-regulated genes, we used expression profiling and HDACi in lymphoid cells. Next, using the flow cytometry and quantitative reverse transcription-PCR, we measured differentiation changes in gene and protein expression after HDACi treatment. RESULTS: Luciferase assay showed repression of granzyme B expression by ETV6/RUNX1 protein and the reversibility of this effect by HDACi. Proving this regulatory role of ETV6/RUNX1, we identified, using complex statistical analysis, 25 genes that are potentially regulated by ETV6/RUNX1 protein. In four selected genes with known role in the cell cycle regulation (JunD, ACK1, PDGFRB, and TCF4), we confirmed expression changes after HDACi by quantitative analysis. After HDACi treatment, ETV6/RUNX1-positive cells showed immunophenotype changes resembling differentiation process compared with other leukemic cells (BCR/ABL, ETV6/PDGFRB positive). Moreover, ETV6/RUNX1-positive leukemic cells accumulated in G(1)-G(0) phase after HDACi whereas other B-lineage leukemic cell lines showed rather unspecific changes including induction of apoptosis and decreased proliferation. CONCLUSIONS: Presented data support the hypothesis that HDACi affect ETV6/RUNX1-positive cells via direct interaction with ETV6/RUNX1 protein and that treatment with HDACi may release aberrant transcription activity caused by ETV6/RUNX1 chimeric transcription factor.
- 650 _2
- $a apoptóza $x účinky záření $7 D017209
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a protein PEBP2A2 $x fyziologie $x genetika $7 D050676
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese u leukemie $x účinky léků $7 D015973
- 650 _2
- $a granzymy $x genetika $7 D053804
- 650 _2
- $a histondeacetylasy $7 D006655
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfoidní leukemie $x genetika $x patologie $7 D007945
- 650 _2
- $a lymfopoéza $x genetika $x účinky léků $7 D038041
- 650 _2
- $a protoonkogenní proteiny c-ets $x fyziologie $x genetika $7 D050783
- 650 _2
- $a represorové proteiny $x fyziologie $x genetika $7 D012097
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 650 _2
- $a inhibitory histondeacetylas $7 D056572
- 700 1_
- $a Madžo, Jozef, $d 1976- $7 xx0037668
- 700 1_
- $a Cario, Gunnar
- 700 1_
- $a Kalina, Tomáš, $d 1975 říjen 11.- $7 xx0060125
- 700 1_
- $a Ford, Anthony
- 700 1_
- $a Žaliová, Markéta, $d 1979- $7 xx0074371
- 700 1_
- $a Hrušák, Ondřej, $d 1965- $7 xx0036691
- 700 1_
- $a Trka, Jan, $d 1966- $7 xx0036261
- 773 0_
- $w MED00001121 $t Clinical cancer research $g Roč. 13, č. 6 (2007), s. 1726-1735 $x 1078-0432
- 910 __
- $a ABA008 $b x $y 7 $z 0
- 990 __
- $a 20090726182400 $b ABA008
- 991 __
- $a 20131015145416 $b ABA008
- 999 __
- $a ok $b bmc $g 670189 $s 528946
- BAS __
- $a 3
- BMC __
- $a 2007 $b 13 $c 6 $d 1726-1735 $i 1078-0432 $m Clinical cancer research $x MED00001121
- GRA __
- $a NR8316 $p MZ0
- LZP __
- $a 2009-B3/vtme